| Texto completo | |
| Autor(es): |
Sandoval, Cristian
;
Torrens, Francisco
;
Godoy, Karina
;
Reyes, Camila
;
Farias, Jorge
Número total de Autores: 5
|
| Tipo de documento: | Artigo Científico |
| Fonte: | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES; v. 24, n. 15, p. 12-pg., 2023-08-01. |
| Resumo | |
Leukemia invades the bone marrow progressively and, through unknown mechanisms, outcompetes healthy hematopoiesis. Protein arginine methyltransferases 1 (PRMT1) are found in prokaryotes and eukaryotes cells. They are necessary for a number of biological processes and have been linked to several human diseases, including cancer. Small compounds that target PRMT1 have a significant impact on both functional research and clinical disease treatment. In fact, numerous PRMT1 inhibitors targeting the S-adenosyl-L-methionine binding region have been studied. Through topographical descriptors, quantitative structure-activity relationships (QSAR) were developed in order to identify the most effective PRMT1 inhibitors among 17 compounds. The model built using linear discriminant analysis allows us to accurately classify over 90% of the investigated active substances. Antileukemic activity is predicted using a multilinear regression analysis, and it can account for more than 56% of the variation. Both analyses are validated using an internal "leave some out" test. The developed model could be utilized in future preclinical experiments with novel drugs. (AU) | |
| Processo FAPESP: | 20/06982-3 - L-asparaginase quimérica e peguilada: estudo das condições de expressão, produção e purificação de biofármaco antileucêmico inovador com potencial de baixa imunogenicidade |
| Beneficiário: | Adalberto Pessoa Junior |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |